PHARMACY

Fresenius Kabi’s biosimilar Stimufend obtains FDA OK

Stimufend is indicated for the treatment of cancer patients undergoing chemotherapy to reduce the incidence of infection as manifested by febrile neutropenia.
Lannett completes clinical trial subject dosing of biosimilar insulin glargine

Lannett anticipates launching biosimilar insulin glargine in the first half of 2024.
Walmart, UnitedHealth Group partner on health services

Select Walmart Health locations will help improve health outcomes for people by advancing value-based care, powered by Optum clinical capabilities.
Hikma, Glenmark Specialty launch Ryaltris

Ryaltris is used for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients 12 years of age and older.
Axsome Therapeutics receives FDA nod for Auvelity

Auvelity is the first and only oral nmda receptor antagonist for the treatment of major depressive disorder in adults.
Retailers begin offering bivalent COVID-19 booster vaccines

The bivalent vaccines have been authorized for use as a single booster dose at least two months after primary or booster vaccination.
Mayne Pharma welcomes board member, announces deputy chair’s retirement

David Petrie is joining the board and Ian Scholes, deputy chair, will retire from the board at the end of September.
CVS Health to acquire Signify Health for $8B

In 2022, Signify Health's clinicians expect to connect with nearly 2.5 million unique members in-person and virtually.